Literature DB >> 2410736

Prostaglandins and myocardial noradrenaline overflow after sympathetic nerve stimulation during ischemia and reperfusion.

K Schrör, K Funke.   

Abstract

The effects of a stable prostacyclin mimetic, iloprost (30 nmol/l), and of indomethacin (3 mumol/l) on ischemia-plus-reperfusion-induced changes in myocardial hemodynamics and sympathetic nerve function were examined in Langendorff-perfused rabbit heart isolated except for the postganglionic sympathetic cardiac nerves. Noradrenaline overflow was measured during an initial 1-min period of nerve stimulation (S1), compared with an identical stimulation (S2) made after 2 h of low-flow ischemia followed by a 30-min reperfusion period. Myocardial catecholamine content of left ventricular tissue was also measured. Pretreatment with iloprost, indomethacin, or vehicle began 10 min before ischemia. Global ischemia plus reperfusion reduced myocardial catecholamine content by 19% (vehicle), and the reduction was greater in indomethacin-pretreated hearts (37%, p less than 0.05), whereas iloprost increased tissue noradrenaline 18% above vehicle control (p less than 0.05). Initially, nerve stimulation-induced noradrenaline overflow ranged from 213 to 247 pmoles, and was significantly reduced after ischemia and reperfusion, the difference (S1-S2) being 198 pmoles (vehicle) and 117 pmoles (indomethacin), but only 44 pmoles after iloprost pretreatment (all groups p less than 0.01). In addition, iloprost improved the recovery of active systolic pressure development, coronary perfusion and left ventricular compliance on reperfusion, whereas a tendency toward further deterioration was observed in indomethacin-pretreated hearts. The results suggest that iloprost may protect both myocardial muscle and nerve cells from ischemia-plus-reperfusion injury. Preservation of myocardial catecholamine levels and sympathetic nerve responsiveness may contribute to improved recovery of reperfused ischemic myocardium.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410736     DOI: 10.1097/00005344-198500075-00011

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

1.  Prostacyclin and iloprost: equal efficiency in preserving high energy phosphates in the dog heart following coronary artery ligation.

Authors:  M Pissarek; H Goos; J Nöhring; J Graff; G Buller; I Beyerdörfer; H J Mest; K F Lindenau; E G Krause
Journal:  Basic Res Cardiol       Date:  1987 Nov-Dec       Impact factor: 17.165

2.  Protection of the ischemic myocardium from reperfusion injury by prostaglandin E1 inhibition of ischemia-induced neutrophil activation.

Authors:  K Schrör; C Thiemermann; P Ney
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-09       Impact factor: 3.000

3.  Alpha2-adrenoreceptor mediated sympathoinhibition of heart rate during acute hypoxia is diminished in conscious prostacyclin synthase deficient mice.

Authors:  James T Pearson; Mikiyasu Shirai; Chieko Yokoyama; Hirotsugu Tsuchimochi; Daryl O Schwenke; Akito Shimouchi; Kenji Kangawa; Tadashi Tanabe
Journal:  Pflugers Arch       Date:  2006-11-22       Impact factor: 3.657

Review 4.  Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning.

Authors:  Roberto Bolli; Ken Shinmura; Xian-Liang Tang; Eitaro Kodani; Yu-Ting Xuan; Yiru Guo; Buddhadeb Dawn
Journal:  Cardiovasc Res       Date:  2002-08-15       Impact factor: 10.787

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.